Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging

Abstract

The growing interest in targeted radionuclide therapy (TRT) for a broad range of applications is shared by a diverse group of medical professionals, including but not limited to physicians and basic scientists in several fields, as well as members of industry, regulatory bodies, and patients. However, no organizational structure is available to regularly bring these stakeholders together to discuss the latest findings and the most productive strategies to ensure that the potential benefits of TRT are realized.

One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer

“…In response to the growing interest in this type of therapy, there have been recent joint workshops by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the National Cancer Institute (NCI) in 2013 and 2014 that have provided forums to discuss the opportunities and challenges of targeted radionuclide therapy. 22 Such interdisciplinary stakeholder gatherings and discussions in combination with increasing clinical experience and educational outreach with approved agents and developments in cancer biology and radiochemistry will assure a significant role for targeted radionuclide therapy in the overall armamentarium of multistep cancer treatment.…”

Future cancer research priorities in the USA: a Lancet Oncology Commission

“…338 Collaboration is needed, and stakeholders include federal agencies, academia, and the pharmaceutical industry. 339–341 Standardisation across devices, patients, and time is necessary and will be addressed by the Quantitative Imaging Biomarkers Alliance (QIBA), and the FDG-PET Uniform Protocols for Imaging in Clinical Trials will inform the QIBA FDG PET Profile 281 for clinical trials of oncological therapies. For nuclear oncology to be successful, coordination between the FDA and the US Center for Medicare and Medicaid Services must be streamlined to ensure reimbursement of the cost of developing new compounds for radionuclide imaging and therapy.…”

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

“…Aside from scientific advancements, key issues need to be worked out for TRT to thrive as a legitimate and active component of cancer therapy [166, 167]. Regulatory and reimbursement agencies must coordinate their requirements so that safety, efficacy, and payment follow seamlessly without major delays for the introduction of the therapy into the clinical setting.…”